BRS3 → BRS1 — Inflammatory Modulation of Neurotransmitter Systems
Inflammatory and redox conditions maintained in BRS3 can alter transmitter synthesis, kynurenine routing and receptor environments in BRS1.
Dependency
BRS3 sets immune and oxidative operating conditions that can divert tryptophan into the kynurenine pathway, change cytokine tone and modify the redox setting of synapses. Those conditions can constrain monoaminergic signalling and excitation–inhibition balance without replacing BRS1 enzymatic regulation.
Principal Routes
| Route | Contribution to BRS1 | Relationship |
|---|---|---|
| Kynurenine-pathway routing of tryptophan | Competes with serotonin synthesis and generates neuroactive kynurenine metabolites | Direct but context-dependent |
| Cytokine and redox environment | Alters receptor, membrane and signalling conditions | Direct |
| Stress-to-inflammation signalling | Can raise inflammatory load that then reaches BRS1 | Mediated through BRS6 (BRS6 → BRS3 → BRS1) |
Network Interpretation
BRS3 is not a neurotransmitter system. Immune activation can reach BRS1 directly through kynurenine and cytokine biology, or indirectly after BRS6 stress signalling increases inflammatory load. Glutathione-centred redox support from BRS2 → BRS3 may further condition this environment.
Boundary and Evidence Status
Kynurenine-pathway chemistry under immune activation is established. The BRS3 → BRS1 dependency is a framework reading of that chemistry. It does not establish that lowering inflammation restores neurotransmitter function or treats ADHD.
Supporting Evidence
- Savitz, 2020 — Reviews how immune activation reshapes neurotransmitter regulation through the kynurenine pathway and related neuroimmune interactions.
- Slavich and Irwin, 2014 — Reviews stress-to-inflammation signalling capable of reshaping central nervous system function; this supports a mediated BRS6 → BRS3 contribution rather than a BRS3-only origin.